Horizon Health International Corp.

June 17, 2010 09:30 ET

Horizon Health International Corp. BCSC-Revocation of Cease Trade Order

MONTREAL, QUEBEC--(Marketwire - June 17, 2010) - HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS:HZHI) (the Company) successfully filed with the BCSC.

The Cease Trade Order imposed on the Company's stock by the BCSC for failing to file has been revoked as of June 15, 2010.

The Order to Revoke:

"The Executive Director of the BCSC orders under section 171 of the Act that the Cease Trade Order is revoked and that trading in the securities of Horizon Health my resume".


The Company, under new management, ordered a total revision of its financials and with yesterday's date has filed all required documents with the BC Securities Commission.

The Company is in full compliance with the US PinkSheet Service and the Company's stock never stopped trading on the US OTC Markets.

THE COMPANY started restructuring by acquiring 'NRL Pharma Canada Inc'. With the great potential of NRL we are looking forward to solid future growth.

The Company's business:

HORIZON's Subsidiary 'NRL Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its Patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin," We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contact Information